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Staphylococcus aureus (MRSA) as the most common organism
to cause healthcare-associated infections in the United States.
Incidence of C. difﬁcile infection (CDI) has also increased in
Canada, Europe, and other parts of the world. CDI is associated
with increased lengths of hospital stay, medical costs, morbidity,
and mortality (attributable mortality rate of 6.9% at 30 days
after diagnosis and 16.7% at 1 year) among hospitalized patients.
Nearly every antibiotic along with gastric acid suppression has
been associated with CDI. Among these, cephalosporins, ampi-
cillin, and clindamycin remain important predisposing agents.
Fluoroquinolones, previously infrequently associated with CDI,
have been found to be one of the primary predisposing an-
timicrobials in recent studies. A positive result of a test for
toxigenic C. difﬁcile and/or its toxins in a patient with diarrhea
is considered to be diagnostic for CDI. Most reports of increases
in the incidence and severity of CDI have been associated with
the BI/NAP1/027 strain of C. difﬁcile. This strain produces more
toxins A and B in vitro than do many other strains of C. difﬁcile,
produces binary toxin, and is highly resistant to ﬂuoroquinolones.
Metronidazole and vancomycin remain the primary options for
the treatment of CDI. Several studies suggest that rates of re-
sponse to treatment of CDI with metronidazole are declining and
statistically superior rates of response to vancomycin treatment
for severe disease with metronidazole treatment. Two antimicro-
bials (nitazoxanide and rifaximin) available in the United States
have been used successfully for CDI treatment but lack United
States Food and Drug Administration approval for this indication.
Experimental treatments currently in clinical development in-
clude a toxin-binding polymer (tolevamer), two poorly absorbed
antimicrobials (OPT-80 [diﬁmicin] and ramoplanin), monoclonal
antibodies, and a C. difﬁcile vaccine. General strategies to
prevent and reduce the risk of CDI include adherence of antimi-
crobial usage restriction and stewardship guidelines, preventing
the patient from being exposed to C. difﬁcile (disinfection and
barrier precautions), and meticulous hand hygiene, and probable
implement of probiotics.
CS2-02 Streptococcus suis Infections in Humans
Constance Schultsz*. Oxford University Clinical Research
Unit/Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
and Center for Poverty-related Communicable Diseases,
Academic Medical Centre, Amsterdam, the Netherlands
Streptococcus suis is a Gram-positive coccus, causing menin-
gitis, septicaemia, pneumonia, and purulent arthritisis in pigs.
Human infection is acquired through exposure to colonized pigs
or contaminated pig meat. Infection is likely to occur through
direct contact, e.g. through skin lesions during butchering, but
other routes of infection, such as gastro-intestinal, cannot be
excluded. In the past few years the number of reported S. suis
infections in humans has increased signiﬁcantly, with most cases
originating in Southeast Asia where there exists a high density
of pig farming. Increased awareness, improved diagnostics and
the occurrence of outbreaks have contributed to this increase.
Meningitis and sepsis are the most common clinical manifestation
of human S. suis infection. In Vietnam, S. suis is the most com-
mon cause of acute bacterial meningitis in adults. Infections in
children are extremely rare. Meningitis is frequently complicated
by sensineural hearing loss. Adjuvant treatment with dexam-
ethasone is associated with protection against the hearing loss
in S. suis meningitis. S. suis is sensitive to penicillin, although in
very rare cases penicillin resistance has been reported, but high
rates of resistance to tetracycline and erythromycine have been
reported from human and pig isolates worldwide.
Human infections are almost always caused by S. suis serotype 2
(determined by the capsule polysaccharide), whilst infection in
pigs is caused by a number of the 35 known serotypes. Molecular
typing suggests that a very limited number of clones is respon-
sible for human infection. Whole genome sequencing of S. suis
serotype 2 strains indicates that strains of the same clonal com-
plex are highly related and that variation predominantly occurs
through horizontal transfer of mobile genetic elements.
Increased awareness from both clinicians and microbiologists is
needed to fully appreciate the importance of S. suis as a human
pathogen.
CS2-03 Streptococcus pyogenes Emm Type,
Superantigens and Macrolid Resistance
Xuzhuang Shen*. Education Department, Beijing Children’s
Hospital Afﬁliated to Capital Medical University, Beijing, China
Group A streptococci (GAS) are one of the most common human
pathogens that cause both invasive and noninvasive infections.
GAS associated diseases are more common in children than adults
and clinical presentation ranges from pharyngitis and impetigo
to invasive infections particularly acute rheumatic fever and
acute glomerulonephritis. The M protein is an important viru-
lence determinant in GAS which is determined by the emm gene.
Currently, more than 170 emm types and 750 emm subtypes of
group A streptococci have been described. Studies of GAS emm
typing distribution performed worldwide, have shown a differing
distribution of emm types in different countries and regions SAgs
are thought to contribute to the pathogenesis of severe GAS
infections by virtue of their potent immunostimulatory activ-
ity and the distribution of proﬁles of genes encoding SAgs has
been used as an additional epidemiological tool to explore the
genomic heterogeneity and possible correlation between toxin
gene content and disease type. Since the late 1990s, resistance
to macrolides has been increasingly detected in S. pyogenes in
several European countries and other parts of the world such as
Korea. There are two primary phenotypes of macrolide resistance
in S. pyogenes: the M phenotype mediated by the mef genes and
the MLSB phenotype mediated by the ermB genes. The latter
phenotype can be constitutive, generally mediated by the ermB
gene, or inducible, generally mediated by the ermA subclass TR
(ermA) gene. Many studies have presented evidence that the
phenotypes and R genes of S. pyogenes have changed over time.
We analyzed the emm type and detected the susceptibilities of
antibiotics to these strains and their phenotype of macrolide
resistance. We also investigated the virulence factors including
the superantigens of the strains. Here, we will report that there
were high resistance rates against macrolides in GAS isolates
collected from Chinese pharyngitis and scarlet fever patients
and that the R-gene was mainly the ermB gene. We also found
that the pattern of the emm-type distribution of GAS strains
from Chinese pediatric patients changed with time and there is a
change in the antimicrobial susceptibility and distribution of the
R-gene in a large collection of S. pyogenes clinical isolates from
pediatric patients during the periods 1993 to 1994 and 2005 to
2008, and to establish its association with the emm-type shift.
CS2-04 VanA Type Vancomycin Resistant Enterococci in
China
Bo Zheng. Institute of Clinical Pharmacology, Peking University
First Hospital, Beijing, China
Most of the vanA type VRE in China were E. faecium. The re-
sistance rates of the vanA type vancomycin reisitant entericocci
isolates to erythromycin, levoﬂoxacin, ampicillin and rifampin
were 96.7%, 91.7%, 88.3% and 80.8%. All VRE isolates were
susceptible to linezolid. Multilocus sequence typing (MLST) iden-
tiﬁed most of the VRE isolates belonged to clonal complexes
CC17. Vancomycin resistance of vanA type E. faecium isolates
was transferred at a frequency of 7.0 ×10-1 to 2.3×10-7 between
E. faecium strains during ﬁlter mating. Two of the plasmids,
pZB18 (67 kbp) and pZB22 (200 kbp), were highly conjugative
and were able to transfer at high frequencies of around 10-4 and
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10-7 per donor cell in broth mating, respectively. Tn1546-like
elements encoding vanA-type VRE were classiﬁed into ten types,
and most of them contained both IS1216V and IS1542 insertions.
The results suggested that the disseminations of VRE were by
Tn1546-like elements being acquired by the conjugative plasmids
and transferred among E. francium strains.
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CS3-01 Cryptococcosis in AIDS Patients: From Research
to Practices in Resource-Limited Settings
Somnuek Sungkanuparph*. Division of Infectious Diseases,
Department of Medicine, Faculty of Medicine Ramathibodi
Hospital, Mahidol University, Bangkok, Thailand
Cryptococcosis is the most common life-threatening fungal infec-
tion among AIDS patients in resource-limited settings. It almost
always occurs in patients with severe immunodeﬁciency and
HIV-infected patients in resource-limited settings usually present
with advanced HIV disease. The mortality rate from cryptococ-
cosis in these settings is relatively high even with antifungal
treatment. Several randomized clinical trials have demonstrated
that primary prophylaxis with ﬂuconazole reduces the incidence
of cryptococcosis in patients with advanced HIV disease, partic-
ularly those with CD4 counts <100 cells/μL. A controlled trial in
Thailand also demonstrated a survival beneﬁt. Although primary
prophylaxis for cryptococcosis is not generally recommended in
high-income countries, it may be more beneﬁcial in resource-
limited countries because of the higher incidence of disease
and the limited capacity of diagnosis and treatment. Primary
prophylaxis with ﬂuconazole is recommended in Thailand for
years while the recent WHO guidelines for essential prevention
of opportunistic infections suggest that azole prophylaxis should
be considered for HIV-infected patients with WHO clinical stage 4
or CD4 <100 cells/μL, whether they are on antiretroviral therapy
(ART) or not. A study of antifungal susceptibilities of Cryptococ-
cus neoformans isolates has shown that the MICs of ﬂuconazole
are not higher with ﬂuconazole prophylaxis.
Treatment of choice for cryptococcosis includes combination
of amphotericin B and ﬂucytosine for 2 weeks and followed
with ﬂuconazole 400 mg/day for 8-10 weeks. However, ﬂucyto-
sine is not available in most developing countries. Prior studies
of combination of amphotericin B and ﬂuconazole had shown
controversial outcomes. A recent randomized, phase II trial in
Thailand and the United States has compared the safety and
efﬁcacy of amphotericin B with that of amphotericin B plus
low-dosed or high-dosed ﬂuconazole. There are no differences
in treatment-related toxicities among the three arms. A trend
towards better outcomes in the combination therapy arms is
seen at days 42 and 70. These results have signiﬁcant treatment
implications and should be validated in a randomized phase III
trial.
In the pre-ART era, relapses were frequent and secondary pro-
phylaxis with ﬂuconazole had been recommended for life-long.
The studies of ART initiation among patients with cryptococcosis
in resource-limited settings have shown that the incidence of new
cases and rate of relapsed disease are dramatically reduced, and
the survival has markedly increased. Prospective studies from
resource-limited settings had also demonstrated that discontin-
uation of secondary prophylaxis is safe when patients achieve
successful immune restoration from ART.
Cryptococcal immune reconstitution inﬂammatory syndrome (C-
IRIS) is characterized a clinical deterioration of cryptococcosis
following initiation of ART. Some studies report that C-IRIS is
observed more frequently in severely immunocompromised pa-
tients with disseminated infection or early ART initiation after
cryptococcosis. This may partly explain the high incidence of
C-IRIS in resource-limited settings. However, a standard case
deﬁnition of C-IRIS has not been available. The International
Network for the Study of HIV-associated IRIS has been working
for the practical case deﬁnition of C-IRIS to provide a tool for
clinical use, particularly in resource-limited settings, and future
epidemiologic studies.
CS3-02 Harnessing Multidrug Resistance Gene Expression
for Effective Antifungal Strategies by a Natural
Product Berberine
Lixin Zhang*. Institute of Microbiology, Chinese Academy of
Sciences, Beijing, China
The effectiveness of existing drugs is increasingly compromised
by the emergence of drug-resistant pathogens. Upregulating
multidrug-resistance (MDR) pumps, which confers enhanced re-
sistance to chemically unrelated alien substances, is a major
source of microbial drug resistance. A major challenge in devel-
oping efﬁcacious antibiotics against drug-resistant pathogens is
to identify compounds that could counteract MDR functions. In
the human pathogen Candida albicans, Mdr1p plays a key role in
azole-resistant clinical isolates.
Here we report an unexpected consequence of MDR1 upreg-
ulation: it confers enhanced sensitivity to a natural product,
berberine. This effect of MDR1 overexpression is at least in part
due to enhanced accumulation of berberine inside cells. In sup-
port of this notion, a number of berberine structural analogues
exhibited a similar MDR1-dependent antifungal activity. We also
show that berberine is indeed highly efﬁcacious in inhibiting
the growth of azole-resistant clinical C. albicans isolates with
upregulated MDR1 from HIV infected patients. Our study reveals
a novel function of MDR1 in raising sensitivity of drug-resistant
fungal pathogens to selected natural products. Thus, the drug
resistance phenotype conferred by MDR1 overexpression could be
harnessed through the use of MDR1-dependent cytotoxic agents,
such as berberine, for effective antifungal strategies.
CS3-03 Combination Antifungals – Is There a Role?
B.H. Tan*. Department of Internal Medicine, Singapore General
Hospital, Singapore
Traditionally, antibiotics have been combined to treat polymicro-
bial infections, in initial therapy, and to prevent the emergence
of resistance. For years, the hope has been that combining anti-
fungals would produce the same effects. In medical mycology,
however, very few combinations have made it to standard recom-
mendations. The combination of amphotericin B and ﬂucytosine
in the initial treatment of cryptococcal meningitis is a case in
point. That combining antifungals is not yet quite standard prac-
tice stems from problems in interpreting the literature. The same
combination of drugs have produced different results in different
laboratories! This likely has to do with the fact that most of the
tests are not standardized. Further, the best clinical data come
only from retrospective studies. In this talk the literature on
combinatino antifungals will be reviewed.
CS3-04 The Echinocandins and Formulary Decision
Mamie Hui *. Department of Microbiology, the Chinese University
of Hong Kong, Hong Kong, China
Invasive fungal infections have always been a difﬁcult to treat
infectious diseases with high mortality. This is due to the im-
munocompromised state of the patients as well as toxicities
of antifungal treatments. Traditionally, only the azoles and the
polyenes are available for treatment of these patients. Recently,
a novel class of antifungal agents, the echinocandins, have
emerged with promising safety proﬁles. These agents act by
inhibiting the synthesis of 1,3-β-D-glucan of fungal cell wall.
